Eribulin mesylate halaven fda approval date?

When was Eribulin mesylate (HALAVEN) approved by the FDA?

HALAVEN (eribulin mesylate) received FDA approval on November 15, 2010 [1].

What was HALAVEN first approved for?

The FDA’s initial approval for HALAVEN was for treatment of patients with metastatic breast cancer who had received prior chemotherapy for metastatic disease, including at least one anthracycline- and one taxane-based regimen (unless those were not appropriate) [1].

Why might you see different dates online?

Different sites sometimes show dates for related events (such as label updates, approvals for additional indications, or regulatory filings) rather than the original FDA approval date. The date above refers to the first FDA approval of HALAVEN [1].

Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202752